Article thumbnail

Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay

By E. Verronèse, A. Delgado, Jenny Valladeau-Guilemond, G. Garin, S. Guillemaut, Olivier Tredan, Isabelle Ray-Coquard, Thomas Bachelot, A. N'Kodia, C. Bardin-dit-Courageot, C. Rigal, D. Pérol, Christophe Caux and Christine Ménétrier-Caux

Abstract

International audienceMonitoring functional competence of immune cell populations in clinical routine represents a major challenge. We developed a whole-blood assay to monitor functional competence of peripheral innate immune cells including NK cells, dendritic and monocyte cell subsets through their ability to produce specific cytokines after short-term stimulation, detected through intra-cytoplasmic staining and multi-parametric flow-cytometry. A PMA/ionomycin T cell activation assay complemented this analysis. Comparing cohorts of healthy women and breast cancer (BC) patients at different stages, we identified significant functional alteration of circulating immune cells during BC progression prior to initiation of treatment. Of upmost importance, as early as the localized primary tumor (PT) stage, we observed functional alterations in several innate immune populations and T cells i.e. (i) reduced TNFalpha production by BDCA-1+ DC and non-classical monocytes in response to Type-I IFN, (ii) a strong drop in IFNgamma production by NK cells in response to either Type-I IFN or TLR7/8 ligand, and (iii) a coordinated impairment of cytokine (IL-2, IFNgamma, IL-21) production by T cell subpopulations. Overall, these alterations are further accentuated according to the stage of the disease in first-line metastatic patients. Finally, whereas we did not detect functional modification of DC subsets in response to TLR7/8 ligand, we highlighted increased IL-12p40 production by monocytes specifically at first relapse (FR). Our results reinforce the importance of monitoring both innate and adaptive immunity to better evaluate dysfunctions in cancer patients and suggest that our whole-blood assay will be useful to monitor response to treatment, particularly for immunotherapeutic strategie

Topics: Flow Cytometry, Cytokines, Adaptive Immunity, analysis, blood, Breast, Cells, France, Immunotherapy, Medical Oncology, Monocytes, Patients, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer
Publisher: 'Informa UK Limited'
Year: 2016
DOI identifier: 10.1080/2162402X.2015.1100791
OAI identifier: oai:HAL:hal-01796186v1
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://hal-univ-lyon1.archive... (external link)
  • https://hal-univ-lyon1.archive... (external link)
  • https://hal-univ-lyon1.archive... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.